pub 30day FRN

27857

Federal Register / Vol. 86, No. 98 / Monday, May 24, 2021 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Total ...........................................

150 ...................................................

Dated: May 11, 2021.
Cesar E. Perez-Gonzalez,
Training Director, National Eye Institute,
National Institutes of Health.
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Heart, Lung,
and Blood Advisory Council, June 08,
2021, 10:00 a.m. to June 08, 2021, 05:00
p.m., NIH, Rockledge 1, 6705 Rockledge
Dr, Bethesda, MD 20892 which was
published n the Federal Register on
May 05, 2021, 294922.
The notice is amended to change the
time of the meeting’s public portion to
12:00 p.m. through 5:00 p.m. The
meeting is partially closed to the public.
Dated: May 19, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–10894 Filed 5–21–21; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 30 Day Comment
Request; The Impact of Clinical
Research Training and Medical
Education at the Clinical Center on
Physician Careers in Academia and
Clinical Research (Clinical Center)
National Institutes of Health,

HHS.
khammond on DSKJM1Z7X2PROD with NOTICES

ACTION:

Notice.

150

........................

In compliance with the
requirement of the Paperwork
Reduction Act of 1995, for opportunity
for public comment on proposed data
collection projects, the Clinical Center,
the National Institutes of Health (NIH)
will publish periodic summaries of
proposed projects to be submitted to the
Office of Management and Budget
(OMB) for review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30 days of the date of this
publication.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, contact: Robert
M. Lembo, MD, Office of Clinical
Research Training and Medical
Education, NIH Clinical Center,
National Institutes of Health, 10 Center
Drive, Room 1N252C, Bethesda, MD
20892–1158, or call non-toll-free
number (301) 496–2636, or Email your
request, including your address to:
[email protected]. Formal requests
for additional plans and instruments
must be requested in writing.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register February 25, 2021 on pages
11550–11551 (86 FR 11550) and
allowed 60 days for public comment. No
public comments were received. The
purpose of this notice is to allow an
additional 30 days for public comment.
The Clinical Center, National Institutes
of Health, may not conduct or sponsor,
and the respondent is not required to

Average time
per response
(in hours)

Total annual
burden hour

450

respond to, an information collection
that has been extended, revised, or
implemented on or after October 1,
1995, unless it displays a currently valid
OMB control number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: The Impact of
Clinical Research Training and Medical
Education at the Clinical Center on
Physician Careers in Academia and
Clinical Research, 0925–0602.
Expiration Date: 11/30/2022,
REVISION, Clinical Center (CC),
National Institutes of Health (NIH).
Need and Use of Information
Collection: The information collected
will allow continued assessment of the
value of the training provided by the
Office of Clinical Research Training and
Medical Education (OCRTME) at the
NIH Clinical Center and the extent to
which this training promotes (a) patient
safety; (b) research productivity and
independence; and (c) future career
development within clinical,
translational, and academic research
settings. The information received from
respondents is presented to, evaluated
by, and incorporated into the ongoing
operational improvement efforts of the
Director of the Office of Clinical
Research Training and Education, and
the Chief Executive Officer of the NIH
Clinical Center. This information will
enable the ongoing operational
improvement efforts of the OCRTME
and its commitment to providing
clinical research training and medical
education of the highest quality to each
trainee.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours 478.

SUMMARY:

[FR Doc. 2021–10820 Filed 5–21–21; 8:45 am]

AGENCY:

Number of
responses per
respondent

Number of
respondents

Type of respondent

ESTIMATED ANNUALIZED BURDEN HOURS
Form name

CRTP/MRSP Alumni Survey ................................

VerDate Sep<11>2014

17:32 May 21, 2021

Number of
respondents

Type of respondents

Jkt 253001

Post Doctoral Students

PO 00000

Frm 00033

Fmt 4703

Sfmt 4703

Number of
responses per
respondent

704

E:\FR\FM\24MYN1.SGM

1

24MYN1

Average
burden per
response
(in hours)
20/60

Total annual
burden hours
requested
235

27858

Federal Register / Vol. 86, No. 98 / Monday, May 24, 2021 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Average
burden per
response
(in hours)

Number of
responses per
respondent

Total annual
burden hours
requested

Type of respondents

Summer Internship Program Alumni Survey ........
Graduate Medical Education Graduate Survey ....
Clinical Electives Program 1 Year Alumni Surveys.

Pre Doctoral Students ..
Physicians ....................
Physicians ....................

280
350
100

1
1
1

20/60
20/60
20/60

93
117
33

Total ...............................................................

.......................................

........................

1,434

........................

478

Dated: May 11, 2021.
Frederick D. Vorck, Jr.,
Project Clearance Liaison, NIH Clinical
Center, National Institutes of Health.
[FR Doc. 2021–10815 Filed 5–21–21; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: P2Y14 Receptor
Antagonists To Treat Kidney and Lung
Inflammation
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

National Institute of Diabetes
and Digestive and Kidney Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the SUPPLEMENTARY INFORMATION
section of this notice to Kantum Pharma
Inc. (Kantum), located in Boston,
Massachussets.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Diabetes and Digestive and Kidney
Diseases’ Technology Advancement
Office on or before June 8, 2021 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Betty B. Tong, Ph.D., Senior
Licensing and Patenting Manager,
NIDDK Technology Advancement
Office, Telephone: 301–451–7836;
Email: [email protected].
SUPPLEMENTARY INFORMATION:
SUMMARY:

khammond on DSKJM1Z7X2PROD with NOTICES

Number of
respondents

Form name

Intellectual Property
1. HHS Ref. No.: E–213–2015–0;
Entitled: Triazole Derivatives as

VerDate Sep<11>2014

17:32 May 21, 2021

Jkt 253001

P2Y14 Receptor Antagonists;
Inventors: Kenneth Jacobson, Ph.D.
et al
(i) U.S. Patent No. 10,683,277; HHS
Ref. No.:
E–213–2015–0–US–05; Issue Date:
June 16, 2020
(ii) EP Patent Application 16774825.0;
HHS Ref. No.:
E–213–2015–0–EP–04; Filing Date:
April 19, 2018
(iii) Chinese Patent No. ZL
201680064441.5; HHS Ref. No.: E–
213–2015–0–CN–03; Issue Date:
March 19, 2021
2. HHS Reference No. E–028–2018–1;
Entitled: P2Y14 Receptor
Antagonists Containing a Biaryl
Core; Inventors: Kenneth Jacobson,
Ph.D. et al
(i) Australian Patent Application
2019218256; HHS Ref. No.: E–028–
2018–1–AU–02; Filing Date: July
28, 2020
(ii) Canadian Patent Application
3,090,788; HHS Ref. No.: E–028–
2018–1–CA–03; Filing Date: August
7, 2020
(iii) Chinese Patent Application
201980012696.0; HHS Ref. No.: E–
028–2018–1–CN–04; Filing Date:
August 10, 2020
(iv) EP Patent Application
19707559.1; HHS Ref. No.: E–028–
2018–1–EP–05; Filing Date: July 20,
2020
(v) Japanese Patent Application 2020–
542580; HHS Ref. No.: E–028–
2018–1–JP–06; Filing Date: August
6, 2020
(vi) U.S. Patent Application 16/
967,177; HHS Ref. No.: E–028–
2018–1–US–07; Filing Date: August
4, 2020
3. HHS Reference No. E–051–2021–0;
Entitled: Heterocyclic P2Y14
Receptor Antagonists; Inventors:
Kenneth Jacobson, Ph.D. et al
(i) U.S. Provisional Patent Application
No.:
62/643,015; HHS Ref. No.: E–051–
2021–0–US–01; Filing Date: January
18, 2021

PO 00000

Frm 00034

Fmt 4703

Sfmt 4703

The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license’
territory may be worldwide and the
field of use may be limited to
‘‘Commercial development of P2Y14
receptor antagonists for the prevention
and treatment of conditions or diseases
associated with inflammation in the
kidney and lung in humans, as claimed
in the Licensed Patent Rights’’.
The inventions pertain to the
composition and use of selective
antagonists for the P2Y14 receptor, a
purinergic G protein-coupled receptor
that is activated by extracellular UDPglucose and related nucleotides. These
P2Y14R antagonists can be developed as
potential drug for the treatment of
inflammation and other disorders
associated with P2Y14R regulated
functions.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Institute of Diabetes and Digestive and
Kidney Diseases receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available. License applications
submitted in response to this Notice
will be presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.

E:\FR\FM\24MYN1.SGM

24MYN1